Nirmatrelvir-ritonavir for COVID-19

McDonald and Lee present several facts about nirmatrelvir-ritonavir. Ritonavir-boosted nirmatrelvir is a Health Canada-approved oral antiviral medication with activity against SARS-CoV-2 Treatment is indicated for adult (≥ 18 yr) outpatients with nonhypoxic COVID-19 who are at high risk of severe di...

Full description

Saved in:
Bibliographic Details
Published in:Canadian Medical Association journal (CMAJ) 2022-02, Vol.194 (6), p.E218-E218
Main Authors: McDonald, Emily G, Lee, Todd C
Format: Article
Language:English
Subjects:
Administration, Oral
Antiretroviral drugs
Antiviral agents
Antiviral drugs
Complications and side effects
Coronaviruses
COVID-19
COVID-19 Drug Treatment
COVID-19 vaccines
Cytochrome P-450 CYP3A Inhibitors - therapeutic use
Drug Combinations
Drug dosages
Drug Interactions
Drug therapy, Combination
Humans
Inhibitor drugs
Lactams - therapeutic use
Leucine - therapeutic use
Nitriles - therapeutic use
Practice
Proline - therapeutic use
Ritonavir - therapeutic use
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Viral Protease Inhibitors - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:McDonald and Lee present several facts about nirmatrelvir-ritonavir. Ritonavir-boosted nirmatrelvir is a Health Canada-approved oral antiviral medication with activity against SARS-CoV-2 Treatment is indicated for adult (≥ 18 yr) outpatients with nonhypoxic COVID-19 who are at high risk of severe disease progression.
ISSN:0820-3946
1488-2329
DOI:10.1503/cmaj.220081